
Science and discovery
DNA study expands the map of how people respond to medicines
Researchers have identified 17,704 previously unreported DNA variants in genes linked to medication response, expanding the information that could help clinicians choose medicines and doses more precisely.
The University of Pittsburgh-led team analysed DNA sequences and health records from nearly 100,000 participants in the US All of Us Research Program. Published in Science Translational Medicine, the study examined 16 genes with established links to how people respond to medicines.
Every participant carried at least one relevant variant. About one in four had been prescribed a medicine known to be affected by a variant they carried. Examples included common treatments for acid reflux and high cholesterol. This does not mean those patients necessarily experienced side effects or received ineffective treatment.
Computer models predicted that around a quarter of the newly identified variants might significantly affect how the body processes drugs. The researchers also documented how common known drug-response variants are across ancestry groups for which data had previously been incomplete, helping address gaps left by genetic research focused largely on people of European ancestry.
The findings strengthen the foundation for more personalised prescribing, but the study did not prove that genetic testing would improve outcomes for every participant. Genes are only part of the picture: age, kidney and liver function, and other medicines also influence treatment response.